Rishi Gupta Biography and Net Worth

Director of Enliven Therapeutics

Rishi is a Partner at OrbiMed Advisors. In addition to Enliven, he serves or has served on the boards of Charm Therapeutics, DELFI Diagnostics, Pionyr Immunotherapeutics, Verona Pharma, Turnstone Biologics, Modis Therapeutics, NeuroPace, Avitide, Dimension Therapeutics, Symbiomix Therapeutics, ChemoCentryx, and Sientra. Rishi has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae, and ORIC Pharmaceuticals. Prior to OrbiMed, Rishi worked as a healthcare investment banker at Raymond James & Associates, a Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz.

Rishi received a J.D. from Yale Law School and an A.B. in Biochemical Sciences from Harvard College.

What is Rishi Gupta's net worth?: The estimated net worth of Rishi Gupta is at least $5.45 million as of May 16th, 2024. Mr. Gupta owns 254,814 shares of Enliven Therapeutics stock worth more than $5,453,020 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Gupta may own. Learn More about Rishi Gupta's net worth.
How do I contact Rishi Gupta?: The corporate mailing address for Mr. Gupta and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at [email protected]. Learn More on Rishi Gupta's contact information.
Has Rishi Gupta been buying or selling shares of Enliven Therapeutics?: Rishi Gupta has not been actively trading shares of Enliven Therapeutics within the last three months. Most recently, Rishi Gupta sold 1,033,300 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $22.14, for a transaction totalling $22,877,262.00. Following the completion of the sale, the director now directly owns 254,814 shares of the company's stock, valued at $5,641,581.96. Learn More on Rishi Gupta's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 55 times. They sold a total of 344,713 shares worth more than $7,118,196.83. The most recent insider tranaction occured on November, 19th when insider Joseph P Lyssikatos sold 12,500 shares worth more than $279,125.00. Insiders at Enliven Therapeutics own 25.9% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 11/19/2025.

Rishi Gupta Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2024	Sell	1,033,300	$22.14	$22,877,262.00	254,814

Rishi Gupta Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $21.40

$20.57

$21.79

50 Day Range

MA: $20.84

$17.63

$23.97

2 Week Range

Now: $21.40

$13.30

$25.96

Volume

494,583 shs

Average Volume

498,270 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35